- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02895659
Fluid Management in Patients Undergoing Cardiac Surgery (Hemacetat)
Fluid Management in Patients Undergoing Cardiac Surgery - Effects of an Acetate Versus Lactate Buffered Balanced Infusion Solution on Hemodynamic Stability, a Randomized Controlled Double-blind Trial
Background: Currently used crystalloid solutes have a variable composition and may therefore influence acid-base status, intra- and extracellular water content and plasma electrolyte compositions and have a major impact on organ function and outcome. Despite continuing evaluation no superiority of one particular type of fluid has been reached so far. To the best of the investigators' knowledge no study in humans has ever assessed whether the type of crystalloid fluid given for fluid resuscitation in patients undergoing cardiac surgery has an impact on hemodynamic stability and cardiac function so far. Nonetheless in the animal model it was shown that the choice of crystalloid fluid may greatly influence cardiac performance
Primary Aim: In this study the investigators want to clarify whether a balanced type acetate-buffered fluid solution in patients undergoing cardiac surgery is associated with better hemodynamic stability and cardiac function than a lactate-buffered crystalloid solute.
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
-
Bern, Svizzera, 3010
- Department of Intensive Care, Bern University Hospital and University of Bern, Bern, Switzerland
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Elective single heart valve replacement
- Elective double valve replacement
- Elective single or double valve replacement and coronary artery bypass grafting
Exclusion Criteria:
- Patients unable to give informed consent
- Patients younger than 18 years of age or older than 80 years
- Pregnancy or breastfeeding
- Ejection fraction (EF) of less than 30% preoperatively
- Preexisting renal insufficiency with a glomerular filtration rate below 30ml/min
- Patients transferred form the intensive care unit to the operating theater
- Emergency operation
- Reoperation
- Patients planned for fast-track surgery
- Patients planned for minimal extracorporal circuits
- Preexisting anemia requiring immediate perioperative blood transfusion
- Chronic inflammatory diseases
- Any signs of infection or sepsis
- Limitation of full therapy (e.g. Jehowa's witnesses)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Ringer lactate
Fluid resuscitation will be performed with lactated Ringers during the perioperative period.
Perioperative hemodynamic management will be performed according to a specified treatment protocol.
|
Perioperative hemodynamic management will be performed according to a specified treatment protocol.
|
Comparatore attivo: Ringer acetate
Fluid resuscitation will be performed with acetated Ringers during the perioperative period.
Perioperative hemodynamic management will be performed according to a specified treatment protocol.
|
Perioperative hemodynamic management will be performed according to a specified treatment protocol.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Cumulative dose of inopressors (norepinephrine and epinephrine) per kg bodyweight/hour during the perioperative period
Lasso di tempo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Time on inopressors
Lasso di tempo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Cumulative dose of inodilators
Lasso di tempo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Time on inodilators
Lasso di tempo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Cumulative dose of vasodilatators
Lasso di tempo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Time on vasodilatators
Lasso di tempo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Total amount of fluid
Lasso di tempo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Changes in acid-base status
Lasso di tempo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Carmen A Pfortmueller, MD, Department of Intensive Care, Bern University Hospital and University of Bern, Bern, Switzerland
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Attributi della malattia
- Malattia critica
- Effetti fisiologici delle droghe
- Agenti adrenergici
- Agenti neurotrasmettitori
- Meccanismi molecolari dell'azione farmacologica
- Agenti autonomi
- Agenti del sistema nervoso periferico
- Alfa-agonisti adrenergici
- Agonisti adrenergici
- Agenti broncodilatatori
- Agenti antiasmatici
- Agenti del sistema respiratorio
- Beta-agonisti adrenergici
- Simpaticomimetici
- Agenti vasocostrittori
- Midriatici
- Noradrenalina
- Epinefrina
- Racepinefrina
- Borato di adrenalina
Altri numeri di identificazione dello studio
- 20160804.1.3
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .